Cancer immunotherapy: Challenges and limitations

被引：113

作者：

Taefehshokr, Sina ^{[1
]}

Parhizkar, Aram ^{[2
]}

Hayati, Shima ^{[3
]}

Mousapour, Morteza ^{[4
]}

Mahmoudpour, Amin ^{[5
]}

Eleid, Liliane ^{[6
]}

Rahmanpour, Dara ^{[7
]}

Fattahi, Sahand ^{[4
]}

Shabani, Hadi ^{[8
]}

Taefehshokr, Nima ^{[9
]}

机构：

[1] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran

[2] Tabriz Univ, Fac Nat Sci, Tabriz, Iran

[3] Islamic Azad Univ, Fac Vet Med, Dept Clin Sci, Karaj Branch, Karaj, Iran

[4] Islamic Azad Univ, Fac Vet Med, Dept Clin Sci, Tabriz Branch, Tabriz, Iran

[5] Tabriz Univ Med Sci, Dept Immunol, Tabriz, Iran

[6] Imperial Coll London, Sect Cell Biol & Funct Genom, London, England

[7] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran

[8] Shahid Chamran Univ Ahvaz, Fac Vet Med, Dept Pathobiol, Ahvaz, Iran

[9] Univ Western Ontario, Ctr Human Immunol, Dept Microbiol & Immunol, London, ON, Canada

来源：

PATHOLOGY RESEARCH AND PRACTICE | 2022年 / 229卷

关键词：

Immunotherapy; Immune checkpoints; CAR T-cell therapy; CHIMERIC-ANTIGEN-RECEPTOR; T-CELL THERAPY; TUMOR-INFILTRATING LYMPHOCYTES; TERM-FOLLOW-UP; CYTOKINE RELEASE SYNDROME; IMMUNE ESCAPE MECHANISMS; METASTATIC MELANOMA; ANTITUMOR IMMUNITY; CLINICAL-TRIAL; B-CELL;

D O I：

10.1016/j.prp.2021.153723

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Although cancer immunotherapy has taken center stage in mainstream oncology inducing complete and longlasting tumor regression, only a subset of patients receiving treatment respond and others relapse after an initial response. Different tumor types respond differently, and even in cancer types that respond (hot tumors), we still observe tumors that are unresponsive (cold tumors), suggesting the presence of resistance. Hence, the development of intrinsic or acquired resistance is a big challenge for the cancer immunotherapy field. Resistance to immunotherapy, including checkpoint inhibitors, CAR-T cell therapy, oncolytic viruses, and recombinant cytokines arises due to cancer cells employing several mechanisms to evade immunosurveillance.

引用

页数：13

共 191 条

[1] CAR models: next-generation CAR modifications for enhanced T-cell function [J].